Just a few neoantigens may be enough for T cells to control prostate cancer
By A Mystery Man Writer
Description
In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
Cancers, Free Full-Text
Cancer vaccines: Building a bridge over troubled waters. - Abstract - Europe PMC
Cancer immunotherapy with immune checkpoint inhibitors (ICIs
A primer on recent developments in cancer immunotherapy, with a
T cells in health and disease Signal Transduction and Targeted
Target selection for CAR-T therapy
Engineered T cell therapy for viral and non-viral epithelial
Immunotherapy mechanisms in prostate cancer. a Sipuleucel-T
Neoantigen-specific CD8 T cell responses in the peripheral blood
Informatics for Cancer Immunotherapy
Developing neoantigen-targeted T cell–based treatments for solid
Cancer vaccines: Building a bridge over troubled waters. - Abstract - Europe PMC
The role of regulatory T cells in the pathogenesis and treatment
PDF) Immunotherapy in prostate cancer: current state and future
What Are Neoantigens?
from
per adult (price varies by group size)